Skip to main content
. 2024 Nov 20;16(22):3885. doi: 10.3390/cancers16223885

Table 3.

Ongoing clinical trials of other KRAS single subvariant small molecule inhibitor monotherapies.

Compound Mechanism of Action Clinical Trial Indication Phase of Study
MRTX1133 KRAS G12D inhibitor
  • -

    In advanced solid tumors (NCT05737706)

  • -

    Alone or in combination with adagrasib in advanced solid tumors (NCT05578092)

 1/2
1/2
TSN1611 KRAS G12D inhibitor 1/2
RMC-9805
(RM-036) 		KRAS G12D inhibitor
  • -

    As monotherapy and in combination with RMC-6263 in solid tumors (NCT06040541)

 1
ASP3082 KRAS G12D inhibitor
  • -

    In locally advanced or metastatic solid tumors (NCT06364696)

 1
QLC1101 KRAS G12D inhibitor 1
INCB161734 KRAS G12D inhibitor
  • -

    In advanced or metastatic solid tumors as a single agent or in combination with other anticancer therapies (NCT06179160)

 1